Davenport, IOWA – According to the statement, Pfizer and BioNTech received positive results from the trial on Sept. 20.
They say the trial included 2,268 young participants.
Pfizer and BioNTech officials say the vaccine demonstrated a favorable safety profile and elicited robust neutralizing antibody responses using a two-dose regimen.
As we all know by now, their COVID-19 vaccine is only approved for use in people 12 and older.
The companies will make a formal request for an emergency use authorization for use in children in the coming weeks.
The Food and Drug Administration is expected to take several weeks combing through the data before possibly issuing an emergency use authorization.
This story will be updated as new information become available.